Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a β2-agonist) Compared to Formoterol in Asthmatic Patients

The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.

Inclusion Criteria:

• Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.
• Men and post-menopausal women above 18 years of age.
• Reversible airway obstruction in response to classical beta2-agonist (salbutamol)
• Non/ex-smokers

Exclusion Criteria:

• Any clinically significant disease or disorder other than asthma
• Any clinically relevant abnormal findings at screening examinations
• Treatment with systemic glucocorticosteroids within the past 30 days
• Inhaled corticosteroid use if dosing is not kept constant